ANN ARBOR, Mich., Oct. 30 NanoBio(R) Corporation, abiopharmaceutical company focused on developing and commercializing novelproducts for the prevention and treatment of infectious diseases, todayannounced the addition of Joyce Sutcliffe, Ph.D., as vice president ofresearch.
Sutcliffe brings 26 years of experience in the discovery and design of newantibiotics, with particular emphasis on understanding and overcomingantibiotic resistance. She joined the NanoBio team from Rib-X Pharmaceuticals,where she served as vice president of biology and chief research scientist.
During her tenure at Rib-X Pharmaceuticals and previously at Pfizer andAbbott, Sutcliffe focused on leveraging knowledge about target-basedresistance to help design novel antibiotics that are potent against organismswith antibiotic resistance. She also led teams that evaluated efficacy andpharmacokinetics in animal disease models to ensure safety and compatibilitywith other drugs.
"Antibiotic resistance drives the need for new treatments againsttenacious infectious microorganisms that continue to mutate," said Sutcliffe."For example the rampant explosion of MRSA (methicillin-resistantStaphylococcus aureus) in the community has led to a need for safe anti-infectives. These bacteria are no longer resistant to just antibiotics buthave become multidrug-resistant by adding other resistance mechanisms to theirarmamentarium.
"NanoBio's deep pipeline of topical anti-infectives and mucosal vaccinesis particularly compelling, given the platform technology poses a very lowrisk of resistance while having broad antimicrobial activity against a widerange of infections," Sutcliffe said.
NanoBio's line of anti-infectives are designed to wage a two-prongedattack against bacteria, viruses, and fungi using safe detergents along withhigh-energy nanoemulsions to physically disrupt pathogen membranes and lysemicrobes, said James Baker, Jr., M.D., founder and CSO of NanoBio Corporation.The absence of a specific metabolic target significantly reduces thelikelihood of triggering resistant infections, he added.
"The addition of Dr. Sutcliffe, an internationally recognized anti-infective expert, will enable NanoBio to accelerate the number of productcandidates we take into the clinic for preventing and treating a wide range ofinfections," said Baker.
NanoBio(R) Corporation is a privately held biopharmaceutical companyfocused on developing and commercializing anti-infective products and mucosalvaccines derived from its patented NanoStat(TM) technology platform. Thecompany's lead product candidates are treatments for herpes labialis (coldsores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenzaand hepatitis B. The company's headquarters and laboratory facilities arelocated in Ann Arbor, Mich.
SOURCE NanoBio Corporation